Sentinel lymph node mapping for thick (≥4-mm) melanoma: Should we be doing it?

Annals of Surgical Oncology

Volumn 10, Issue 4, 2003, Pages 408-415

  Carlson, Grant W ^a,c   Murray, Douglas R ^a   Hestley, Andrea ^a   Staley, Charles A ^a   Lyles, Robert H ^b   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Distant metastasis; Prognostic factors; Sentinel lymph node; Thick melanoma

Indexed keywords

ADULT; AGED; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURVIVAL; DATA ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; MULTIVARIATE ANALYSIS OF COVARIANCE; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; SURVIVAL RATE; TUMOR VOLUME; ARTICLE; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; SURVIVAL;

ADULT; AGED; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0042161479     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.03.055     Document Type: Review

References (14)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
2. Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 1994;31:253-374.
3. Kim SH, Garcia C, Rodriguez J, et al. Prognosis of thick cutaneous melanoma. J Am Coll Surg 1999;188:241-7.
4. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7:160-5.
5. Clary BM, Brady MS, Lewis JJ, et al. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-8.
6. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24(1 Suppl 4):S8-10.
7. Pijpers R, Borgstein PJ, Meijer S, et al. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 1997;21:788-92; discussion 793.
8. Murray DR, Carlson GW, Greenlee R, et al. Surgical management of malignant melanoma using dynamic lymphoscintigraphy and gamma probe-guided sentinel lymph node biopsy: the Emory experience. Am Surg 2000;66:763-7.
9. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990;125:322-6.
10. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.
11. Schneebaum S, Briele HA, Walker MJ, et al. Cutaneous thick melanoma. Prognosis and treatment. Arch Surg 1987;122:707-11.
12. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469-74.
13. Zettersten E, Sagebiel RW, Miller JR, et al. Prognostic factors in patients with thick melanoma (> 4 mm). Cancer 2002;94:1049-56.
14. Ferrone CR, Panageas KS, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9:637-45.